Although many treatments have been applied to treat hormone-refractory prostate cancer (HRPC), therapeutic outcome is not altogether satisfactory.
In the case of locally recurring HRPC, uncontrolled gross hematuria, dysuria, and scalding are often experienced. We report a patient who improved following intra-arterial infusion of cisplatin (CDDP) and ifosfamide (IFM) to treat urinary retention caused by locally recurring HRPC. After chemotherapy, cancer volume was remarkably reduced and symptoms improved.
Uemura K, Nishihara K, Hayashi T, Tomiyasu K, Matsuoka K. Are you the author?
Department of Urology, Kurume University School of Medicine, Asahimach 67, Kurume, Fukuoka, Japan.
Reference: J Infect Chemother. 2011 Dec 28. Epub ahead of print.